CA-VERIMATRIX
8.2.2024 17:46:33 CET | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that HBL Microfinance Bank Ltd (HBL MfB) is among the latest financial institutions in the South Asia region to deploy the Verimatrix Extended Threat Defense (XTD) app shielding service to protect FirstPay, the bank’s mobile wallet app.
Earlier this month, HBL MfB added Verimatrix XTD protections to its FirstPay mobile app that has seen 1 million+ downloads to date between the Google Play Store and the Apple App Store. Verimatrix XTD greatly reduces the chances of cybercriminals using the app to infiltrate connected enterprises while deploying the latest obfuscation, anti-tamper and anti-reverse engineering techniques to prevent threats before they can compromise both the mobile app -- and the enterprise.
“We’re pleased to announce that HBL Microfinance Bank’s FirstPay mobile app will now serve its customer base with the reassurance that Verimatrix’s XTD app shielding service is proactively providing the needed protections against attackers looking to exploit app-related vulnerabilities,” said Tom Powledge, Head of Cybersecurity Business for Verimatrix. “It’s through this strategic effort to maximize protections during the ongoing development process that XTD greatly reduces the chances of attack while also providing the visibility and insights needed to identify and remediate potential threats. That’s especially critical for mobile apps that deliver such bedrock services such as basic banking needs to so many.”
Mustafa Jamshed Gillani, Chief Digital & Financial Inclusion Officer at HBL MfB, said “This partnership marks a significant milestone in our journey toward digital financial inclusion and providing safe and secure mobile banking services. At HBL Microfinance Bank, our customers are our priority which is why it is our mandate to offer convenience and financial security through FirstPay. As a mobile wallet backed by a leading microfinance bank, Firstpay is on a mission to provide accessible digital lending solutions to the unbanked.”
Waqas Haider, Chief Information Security Officer at HBL MfB, said, “In line with our leadership’s vision of digital financial inclusion and digital banking for the unbanked, we are strongly geared toward providing secure and stable mobile banking services to our valued customers. In doing so, we put regulatory requirements first and foremost in our approach of secure design. We are proud to have such a focused team with a single vision to deliver stable and secure mobile banking service to our valued customers.”
About HBL Microfinance Bank
HBL Microfinance Bank, was established in 2002 as a nationwide microfinance bank. HBL MfB was created through a structured transformation of the credit and savings section of the Aga Khan Rural Support Programme (AKRSP), an integrated development programme initiated in 1982, to pioneer the microfinance sector. Through targeted financial and multi-sectoral products and services based on the evolving needs of the underprivileged, HBL MfB continues to enable its clients to strengthen their entrepreneurial base and build financial, physical and human capital to secure their future.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208977275/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom